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Purpose/Objective: So far risk stratification and treatment 
decisions in the management of prostate cancer patients are 
based on T stage, Gleason score and PSA value. Currently 
used risk classifications often lead to under- or 
overtreatment. Other parameters to better characterize 
prostate cancer and guide the treatment are urgently 
needed. Therefore we conducted a study correlating miRNA 
expression levels with outcome data. 
Materials and Methods: MiRNA expression levels of eight 
hundred miRNAs of forty three patients who had undergone 
salvage radiation therapy following biochemical failure were 
analyzed using the nCounter human v2 assay (NanoString 
Technologies; Seattle, WA). Formalin-fixed, paraffin-
embedded tissue blocks were used. Expression data were 
correlated with biochemical relapse free survival. Univariate 
and multivariate Cox proportion hazards regression models as 
well as receiver operating characteristics were utilized to 
identify statistically significant miRNAs 
Results: Eighty eight miRNAs were identified to be 
significantly (p36 months). Nine miRNAs were identified to be 
significantly (p 
Conclusions: miRNA signatures can distinguish patients with 
early versus late recurrence after prostatectomy. Two novel 
miRNAs were identified that significantly improve prediction 
of biochemical failure post-salvage radiation therapy 
compared to available clinico-histopathological factors alone, 
supporting the use of miRNAs within clinically used predictive 
models. Both findings warrant further validation studies. 
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Purpose/Objective: Toxicity related to the gastrointestinal 
(GI) and genitourinary GU tract following radiotherapy (RT) 
for prostate cancer involves the interplay between various 
symptoms. The purpose of this study was to investigate the 
robustness of patient-reported symptoms over time to follow-
up within identified symptom groups. 
Materials and Methods: The investigated subjects were 
previously treated in a clinical trial (to explore the toxicity 
and efficacy of pelvic lymph node RT) with intensity-
modulated RT for locally advanced prostate cancer in 2011-
2012 (N=87). Prescribed dose was 78 Gy to the prostate and 
56 Gy to the pelvic lymph nodes in 39 fractions. The patients 
completed the study-specific questionnaire at different time 
points within the first year after RT (at 3, 6, and 12 months). 
This study is based on the 18 and 12 GI and GU symptoms, 
respectively, that directly reflected potential RT-induced 
injuries. For both GI and GU toxicity, symptom groups were 
generated based on interacting symptoms as identified by 
factor analysis (FA). The temporal pattern of symptoms in 
these symptom groups was studied within the first year after 
RT. 
Results: Two GI and two GU symptom groups were identified 
at 3, 6, and 12 months post-RT. Based on the symptoms 
included, the GI symptom groups could be labelled as faecal 
Leakage (4-7 symptoms), and Obstruction (3-7 symptoms), 
and the GU symptom groups as urinary Incontinence (3-8 
symptoms), and Obstruction (3-9 symptoms). Two symptoms 
of each symptom group remained present across the 
investigated time-points. 
Conclusions: Our findings indicate that at least two patient-
reported GI and GU symptoms remain present during the first 
year after RT following RT for locally advanced prostate 
cancer in each investigated symptom group. These symptoms 
have the potential to serve as attractive endpoints in 
quantitative dose-response modelling to better understand 
the temporal pattern of RT-induced causes of the GI - and GU 
tract.  
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Purpose/Objective: To retrospectively evaluate overall 
survival (OS), biochemical and metastatic relapse-free 
survival (bRFS and mRFS), late genitourinary and 
gastrointestinal toxicity in patients (pts) treated with 
adjuvant radiotherapy (ART) or salvage radiotherapy (SRT) 
for prostate cancer. We imported all DVH into an in house 
system (PRODVH) to elaborate means and comparisons within 
groups clinically identified. 
Materials and Methods: From 1999 to 2013, 240 pts were 
selected for the analysis (120 pts treated with ART and 120 
pts treated with SRT). The median follow-up was 50,7 
months. bRFS, mRFS and OS were correlated with age, PSA, 
Gleason Score, T and N stage, surgical margins, radiotherapy 
doses and technique, intention to treat (ASTRO guidelines: 
Int J Radiat Oncol Biol Phys. 2013). Toxicity data were 
collected using the RTOG and CTCAE v.4 scales and 
correlated to radiotherapy doses and technique, PTV and 
organ at risk volume. Kaplan-Meyer and Cox regression were 
performed for survivals and Chi Square test were used for 
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toxicities. Due to the heterogeneity of fractions (fr) number 
we derived an 35 fr LQ equivalent DVH using different a/b: 4 
for prostate, 3 for rectum late toxicity, 4 for bladder late 
toxicity. 
Results: Clinical and therapeutic factors are shown in tab.1. 
At univariate analysis pT3b-T4 and SRT had worse bRFS (data 
confirmed at multivariate Cox regression analysis, p=0,019 
and 0,003); PSA > 10, GS >7 and pT3b-T4 were related to 
significant worse mRFS (only GS confirmed at multivariate 
analysis p=0,028). None variables resulted significant in terms 
of OS.Proctitis (CTCAE scale) occurred more frequently in pts 
treated with 3DCRT vs VMAT (p=0.001), urinary incontinence 
(CTCAE scale) were related to smaller bladder volume (p= 
0,008). Figure 1 shows the DVH comparison between 3D plans 
and VMAT-IGRT. 
Figure 1: DVH comparison between 3D plans and VMAT-IGRT. 
Above DVH represent mean volume for fixed doses. Below 
DVH represent mean dose for fixed volume. 
 
 
 
 
Conclusions: In this series, favorable clinical factors affected 
the survival outcomes and adjuvant radiotherapy seemed to 
have a better bRFS. Toxicity profile was very low and CTCAE 
scale resulted more reliable. PRODVH showed to be a useful 
and simple tool that has potentials to help in retrospective as 
well as in prospective study. Our current aim is to integrate 
PRODVH with the RTPacs in order to move from planning DVH 
to real time DVH as obtained by calculation with daily 
imaging. 
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Purpose/Objective: To quantify long term outcomes in 
patients above and below the age of 60 years treated with 
low dose rate (LDR) permanent prostate seed brachytherapy 
as monotherapy at single centre in the United Kingdom. 
Materials and Methods: Patients received trans-rectal 
ultrasound (TRUS) guided Iodine- 125 brachytherapy as 
monotherapy and were treated at our institution between 
March 1995 and September 2007. Using a pre-plan technique, 
145Gy was delivered to the prostate with a margin of 3mm. 
No patients received supplemental external beam 
radiotherapy. Neo-adjuvant hormonal therapy was only used 
for gland cytoreduction. Clinical staging was according to the 
1997 AJCC TNM system and patients were stratified using the 
Memorial Sloan-Kettering (MSK) model. Outcome data 
collected prospectively was stratified by age less than or 
greater than 60 years. This was analyzed in terms of overall 
survival, disease specific survival and PSA relapse-free 
survival (Nadir+2). Actuarial survival curves were calculated 
using the Kaplan-Meier method.  
 
 
Results: With a median follow up of 6.5 (range 0.2-17.7) 
years, 2157 patients were identified. Patient characteristics 
are shown in (table 1) with 575 (27%) patients treated being 
less than 60 and 1582 (73%) patients over the age of 60 years. 
A higher proportion of patients in the over 60 years cohort 
fell into MSK intermediate and high risk groups (48.8% vs. 
39%). The 10 years overall survival was higher in the <60 
cohort (86% vs. 75% Log Rank p<0.005). Stratified by age, 
death attributed to prostate cancer was 7.1% (n=41) in the 
<60 cohort and 15% (n=238) in the ≥60 cohort. At 10 years 
PSA relapse free survival was significantly higher in patients 
aged under 60 (77% vs. 70% p<0.05).  
